Source 1primary paper2025MED
Toolkit/HIV-1 Gag-based virus-like particles
HIV-1 Gag-based virus-like particles
Also known as: HIV-1 Gag-based VLPs, VLPs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Particularly, HIV-1 Gag-based VLPs are one of the most described platforms for vaccine development, provided their ability for successful pseudotyping either by genetic engineering or click chemistry.
Usefulness & Problems
Why this is useful
This platform uses recombinant HIV-1 Gag expression to assemble and secrete non-infective virus-like particles by cell budding. The particles can be further pseudotyped or functionalized.; vaccine development; particle functionalization and pseudotyping studies
Source:
This platform uses recombinant HIV-1 Gag expression to assemble and secrete non-infective virus-like particles by cell budding. The particles can be further pseudotyped or functionalized.
Source:
vaccine development
Source:
particle functionalization and pseudotyping studies
Problem solved
It provides a vaccine-candidate particle scaffold that can elicit strong immune responses without being infective. It also offers a platform compatible with pseudotyping and surface functionalization.; provides a non-infective particle platform with strong immune-response potential
Source:
It provides a vaccine-candidate particle scaffold that can elicit strong immune responses without being infective. It also offers a platform compatible with pseudotyping and surface functionalization.
Source:
provides a non-infective particle platform with strong immune-response potential
Problem links
provides a non-infective particle platform with strong immune-response potential
LiteratureIt provides a vaccine-candidate particle scaffold that can elicit strong immune responses without being infective. It also offers a platform compatible with pseudotyping and surface functionalization.
Source:
It provides a vaccine-candidate particle scaffold that can elicit strong immune responses without being infective. It also offers a platform compatible with pseudotyping and surface functionalization.
Published Workflows
Objective: Compare how operation mode and productivity-enhancing ATM gene silencing affect the quality attributes, purification behavior, stability, and morphology of HIV-1 Gag-based VLPs produced by transient gene expression in HEK293 cells.
Why it works: The study is based on the premise that VLPs assemble by Gag expression and budding while taking host-cell membrane, so changes in cell line engineering and manufacturing mode can alter particle composition and downstream behavior.
altering specific productivitychanging operation mode from batch to perfusionATM gene silencingtransient gene expression in HEK293 culturesbatch cultureperfusion culturecomparative physicochemical characterizationlipidome analysis
Stages
- 1.VLP production under batch, perfusion, and ATM-silenced conditions(library_build)
The study first needs VLP samples produced under standard batch, perfusion, and ATM-silenced conditions before their quality attributes can be compared.
Selection: Generate HIV-1 Gag-based VLP samples under different operation modes and productivity conditions for downstream comparison.
- 2.Physicochemical characterization of produced VLP samples(functional_characterization)
The paper aims to determine how productivity and operation mode affect VLP quality attributes.
Selection: Measure Gag monomers per VLP, Cy5 functionalization per total particle, and lipid per particle across production conditions.
- 3.Assessment of purification, stability, recovery, and morphology(confirmatory_validation)
The study extends beyond composition measurements to determine whether altered particle properties matter for purification and stability outcomes.
Selection: Evaluate how differential physicochemical properties affect purification and stability, with perfusion highlighted for recovery and lyophilization with preserved morphology.
Steps
- 1.Produce HIV-1 Gag VLPs by transient gene expression in HEK293 cultures under batch and perfusion modes, including ATM-silenced conditionsengineered particle product
Generate condition-specific VLP samples for comparative analysis.
Downstream characterization requires VLP material produced under the contrasted manufacturing and productivity conditions.
- 2.Measure Gag monomers per VLP, Cy5 functionalization per total particle, and lipid per particleassayed particle product
Quantify how productivity and operation mode change VLP quality attributes.
These measurements are needed before interpreting downstream purification and stability behavior.
- 3.Assess the impact of differential physicochemical properties on purification and stability, including recovery and morphology after lyophilizationvalidated particle product
Determine whether condition-dependent quality differences affect downstream handling and preservation.
This step follows physicochemical characterization because the paper explicitly assesses how those differential properties influence purification and stability outcomes.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
click-chemistry-based surface functionalizationpseudotypingself-assembly and budding of hiv-1 gag into virus-like particlesTechniques
No technique tags yet.
Target processes
recombinationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator
The abstract supports a requirement for recombinant Gag expression in HEK293 cells under transient gene expression, with production in batch or perfusion culture. Functionalization measurements also imply downstream particle-labeling workflows.; requires recombinant expression of Gag polyprotein; quality depends on operation mode and specific productivity
The abstract indicates that product quality is not automatically preserved when productivity is increased by metabolic engineering or process intensification. Manufacturing changes can alter stoichiometry, lipid content, purification behavior, and stability.; properties depend on cell line and manufacturing method; quality attributes become unclear when production is enhanced by metabolic engineering or process intensification
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Perfusion-derived nanoparticles achieved functionalization rates of 2800 Cy5 per total particle, whereas batch-produced nanoparticles were below 1000 Cy5 per total particle.
functionalization rate 2800 Cy5/TPfunctionalization rate 1000 Cy5/TP
Lipidome analysis showed a relative decrease in lipid per particle for all studied conditions compared with standard batch production.
HIV-1 Gag-based virus-like particles are a described vaccine-development platform that can be successfully pseudotyped by genetic engineering or click chemistry.
Perfusion enables high VLP recovery and lyophilization with preserved morphology.
A linear negative correlation was found between Gag monomers per VLP and specific productivity in the studied HIV-1 Gag VLP production conditions.
Standard batch production yielded 3100 ± 100 Gag monomers per VLP, perfusion yielded 1900 ± 100, and batch ATM-knockdown yielded 800 ± 60.
Gag monomers per VLP 3100 monomers/VLPGag monomers per VLP 1900 monomers/VLPGag monomers per VLP 800 monomers/VLP
Approval Evidence
1 source6 linked approval claimsfirst-pass slug hiv-1-gag-based-virus-like-particles
Particularly, HIV-1 Gag-based VLPs are one of the most described platforms for vaccine development, provided their ability for successful pseudotyping either by genetic engineering or click chemistry.
Source:
functionalization performancesupports
Perfusion-derived nanoparticles achieved functionalization rates of 2800 Cy5 per total particle, whereas batch-produced nanoparticles were below 1000 Cy5 per total particle.
Source:
lipid composition changesupports
Lipidome analysis showed a relative decrease in lipid per particle for all studied conditions compared with standard batch production.
Source:
platform capabilitysupports
HIV-1 Gag-based virus-like particles are a described vaccine-development platform that can be successfully pseudotyped by genetic engineering or click chemistry.
Source:
process outcomesupports
Perfusion enables high VLP recovery and lyophilization with preserved morphology.
Source:
productivity quality relationshipsupports
A linear negative correlation was found between Gag monomers per VLP and specific productivity in the studied HIV-1 Gag VLP production conditions.
Source:
quantitative compositionsupports
Standard batch production yielded 3100 ± 100 Gag monomers per VLP, perfusion yielded 1900 ± 100, and batch ATM-knockdown yielded 800 ± 60.
Source:
Comparisons
Source-stated alternatives
The abstract contrasts genetic engineering and click chemistry as alternative ways to pseudotype or functionalize the VLP platform.
Source:
The abstract contrasts genetic engineering and click chemistry as alternative ways to pseudotype or functionalize the VLP platform.
Source-backed strengths
natural ability to elicit strong immune responses; can be pseudotyped by genetic engineering or click chemistry
Source:
natural ability to elicit strong immune responses
Source:
can be pseudotyped by genetic engineering or click chemistry
HIV-1 Gag-based virus-like particles and cell-specific receptor subtype gene deletion mouse models address a similar problem space because they share recombination.
Shared frame: same top-level item type; shared target processes: recombination
Strengths here: looks easier to implement in practice.
HIV-1 Gag-based virus-like particles and CheRiff + jRCaMP1b + RH237 cardiac all-optical electrophysiology platform address a similar problem space because they share recombination.
Shared frame: same top-level item type; shared target processes: recombination
Strengths here: looks easier to implement in practice.
Compared with eNpHR
HIV-1 Gag-based virus-like particles and eNpHR address a similar problem space because they share recombination.
Shared frame: same top-level item type; shared target processes: recombination
Strengths here: looks easier to implement in practice; may avoid an exogenous cofactor requirement.
Ranked Citations
- 1.